Adrenocortical carcinoma - null regimens

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main adrenocortical carcinoma page for current regimens.


Recurrent, locally advanced, or metastatic disease

Placebo

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Fassnacht et al. 2015 (GALACCTIC) 2009-2011 Phase III (C) Linsitinib Did not meet primary endpoint of OS

No active antineoplastic treatment.

References

  1. GALACCTIC: Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. link to original article PubMed NCT00924989